Ping An interim profit misses estimates as China rate cut erodes insurer’s investments


The first-half profit of China’s most valuable insurance company missed analysts’ estimates, as one-off revaluations of investments eroded the increasing sales of life and health products by Ping An Insurance (Group).

Interim net profit fell 8.8 per cent to 68.05 billion yuan (US$9.50 billion) from a year earlier, missing a 4.4 per cent increase that was expected by Bloomberg’s consensus estimate.

The value of new business in Ping An’s life and health insurance divisions, a key measure of future growth, rose 39.8 per cent during the period to 25.96 billion yuan, fuelled by strong sales by agents and the bancassurance business.

“China’s economy was generally stable and improved steadily despite pressure from a complex and severe external environment in the first half of 2025, but it still faces short- and medium-term challenges including lacklustre domestic demand,” Ping An chairman Peter Ma Mingzhe said in an earnings statement on Tuesday to the Hong Kong stock exchange after trading hours.

Peter Ma Mingzhe, chairman and chief executive officer of Ping An Insurance (Group). Photo: Xiaomei Chen
Peter Ma Mingzhe, chairman and chief executive officer of Ping An Insurance (Group). Photo: Xiaomei Chen

The Shenzhen-based insurer said it would pay an interim dividend of 0.95 yuan per share, up 2.2 per cent from a year earlier.

  • Related Posts

    China issues new safety rules for OpenClaw. Here are the dos and don’ts

    A unit of China’s Ministry of Industry and Information Technology (MIIT) has issued guidelines on best practices and prohibitions for adopting and using OpenClaw, the popular artificial intelligence agent that…

    Continue reading
    Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

    Eli Lilly has pledged an additional US$3 billion investment in China over the next decade to strengthen its local supply chain and manufacturing capabilities, deepening the footprint of foreign pharmaceutical…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *